PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Researchers find early driver of prostate cancer aggressiveness

Study links higher expression of the gene PROX1 to aggressive change in prostate tumor cells; FDA-approved class of drugs can disable PROX1

2025-06-02
(Press-News.org) For more information, contact:

Nicole Fawcett, nfawcett@umich.edu

 

EMBARGOED for release at noon ET June 2, 2025

 

Researchers find early driver of prostate cancer aggressiveness

Study links higher expression of the gene PROX1 to aggressive change in prostate tumor cells; FDA-approved class of drugs can disable PROX1

 

ANN ARBOR, Michigan — Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.

 

“Patients whose prostate tumors lose reliance on the androgen receptor do poorly. Our results suggest a therapeutic approach for patients whose tumors have undergone that shift,” said senior study author Joshi J. Alumkal, M.D., the Wicha Family Professor of Oncology at the University of Michigan Rogel Cancer Center.

 

The work advances earlier studies that found prostate cancer cells undergo a process called lineage plasticity, in which they become resistant to targeting the androgen receptor, a key target in prostate cancer. This transition away from dependence on the androgen receptor is a continuum with cancer cells taking on alternate identities from what is typical in most prostate cancers that rely on the androgen receptor.

 

In this new study, led by Zhi Duan, Ph.D., and published in the Journal of Clinical Investigation, the team examined which factors might be causing this transition to occur. They identified the gene PROX1, which plays a role in dictating cell identity in both normal cells and cancer cells. The team found that as prostate cancer cells transition to an alternate identity, PROX1 becomes more highly expressed.

 

Their studies implicating PROX1 began by examining patient tumor biopsies that had undergone lineage plasticity. PROX1 was the top upregulated gene. By examining hundreds of patient tumors along the continuum of lineage plasticity, they confirmed PROX1 as an early marker of lineage plasticity. Indeed, they found that tumors with low activity of the androgen receptor (called double-negative prostate cancer) in addition to tumors that completely lose expression of the androgen receptor (called neuroendocrine prostate cancer) turn on PROX1.

 

In additional experiments, the team showed PROX1 expression was inversely correlated with androgen receptor expression in prostate cancer patient tumor datasets. Adding PROX1 to prostate cancer cells also turned off the androgen receptor.

 

“We think PROX1 is regulating the androgen receptor. It may be one explanation for why the androgen receptor gets turned off when tumors undergo lineage plasticity and transition away from the typical glandular prostate cancer identity,” Alumkal said.

 

Next, the team eliminated PROX1 expression with genetic methods in both double-negative prostate cancer and neuroendocrine prostate cancer cells. The cells then stopped growing and began to die, suggesting that targeting PROX1 could be an effective way to control these tumors.

 

One challenge is that PROX1 is a transcription factor, meaning its function to turn on genes, and this type of protein is notoriously difficult to target with drugs. Looking for a workaround, the team turned to the company PROX1 keeps.

 

“We examined the proteins that bind to PROX1. Among the top partners were histone deacetylases, or HDACs. We felt like this was guilt by association. We hypothesized that HDACs might cooperate with PROX1 and that targeting HDACs might be like targeting PROX1,” Alumkal said.

 

HDACs are already known to play a role in cancer, and several HDAC inhibitors have been approved by the U.S. Food and Drug Administration for other cancers other than prostate.  

 

The team found that PROX1-expressing prostate cancer cells were very sensitive to HDAC inhibitors and treatment with these drugs depleted PROX1 protein. As PROX1 expression decreased, the tumor cells died. The impact was similar to when the team genetically removed PROX1 from the cells.

 

“Our work implicates PROX1 as an important early driver away from androgen receptor dependence. HDAC inhibitors can block PROX1 and reduce survival of aggressive prostate tumor models that have transitioned away from androgen receptor reliance. Our results suggest this class of drugs should be prioritized for clinical trials in patients who have aggressive prostate cancer subtypes, for which there are few treatment options,” Alumkal said.

 

Additional authors: Mingchen Shi, Anbarasu Kumaraswamy, Dong Lin, Dhruv Khokhani, Yong Wang, Chao Zhang, Fiana Flores, Eva Rodansky, Olivia A. Swaim, William K. Storck, Hannah Beck, Radhika A. Patel, Erolcan Sayar, Brian P. Hanratty, Hui Xue, Xin Dong, Zoe R. Maylin, Rensheng Wan, David A. Quigley, Martin Sjostrom, Ya-Mei Hu, Faming Zhao, Zheng Xia, Siyuan Cheng, Xiuping Yu, Felix Y. Feng, Li Zhang, Rahul Aggarwal, Eric J. Small, Visweswaran Ravikumar, Arvind Rao, Karan Bedi, John K. Lee, Colm Morrissey, Ilsa Coleman, Peter S. Nelson, Eva Corey, Aaron Udager, Ryan Rebernick, Marcin P. Cieslik, Arul M. Chinnaiyan, Joel A. Yates, Michael C. Haffner, Yuzhuo Wang

 

Funding for this work is from National Institutes of Health grants CA251245, CA282005, CA186786, P30CA046592, T90DE030859, GM147365, CA214955-01A1, CA274336, P50CA97186, CA163227; U.S. Department of Defense grants W81XWH-22-1-0833, HT94252410252, W81XWH2110539; Joint Institute for Cancer Research, Prostate Cancer Foundation, Canadian Institutes of Health Research, Terry Fox Research Institute, Canadian Cancer Society, BC Cancer Foundation, Smith Family Scholar Award, Sheppard Family Foundation, Benioff Initiative for Prostate Cancer Research, Silver Family Innovation Foundation, National Science Foundation grant 2152776, Institute for Prostate Cancer Research

 

Disclosure: None related to the present work.

 

Paper cited: “PROX1 is an Early Driver of Lineage Plasticity in Prostate Cancer,” Journal of Clinical Investigation. 

 

Resources:

University of Michigan Rogel Cancer Center, www.rogelcancercenter.org

Michigan Medicine Cancer AnswerLine, 800-865-1125

# # #

END


ELSE PRESS RELEASES FROM THIS DATE:

Insect protein blocks bacterial infection

2025-06-02
A protein that gives fleas their bounce has been used to boot out bacteria cells, with lab results demonstrating the material’s potential for preventing medical implant infection.   The collaborative study led by researchers at RMIT University in Australia is the first reported use of antibacterial coatings made from resilin-mimetic proteins to fully block bacteria from attaching to a surface.  Study lead author Professor Namita Roy Choudhury said the finding is a critical step towards their ...

New study casts doubt on the likelihood of a Milky Way – Andromeda collision

2025-06-02
Scientists from Helsinki, Durham and Toulouse universities used data from NASA’s Hubble and the European Space Agency’s Gaia space telescopes to simulate how the Milky Way and Andromeda will evolve over the next 10 billion years.   The two galaxies are currently heading towards each other at a speed of about 100 kilometres per second.   A collision would be devastating for both galaxies which would be destroyed, leaving behind a spheroidal pile of stars known as an elliptical galaxy.   The team ran 100,000 simulations of both galaxies based on the latest observational ...

Prevalence of artificial sweetener neotame in U.S.-marketed disposable e-cigarettes

2025-06-02
About The Study: This study demonstrates that the artificial sweetener neotame was a ubiquitous constituent of popular disposable e-cigarettes sold in the U.S. in 2024, including those containing no nicotine or the nicotine analogue 6-methylnicotine. Neotame is 7,000 to 13,000 times sweeter than table sugar and is 35 to 65 times sweeter than aspartame. Corresponding Author: To contact the corresponding author, Sven E. Jordt, PhD, email sven.jordt@duke.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2025.7398) Editor’s ...

E-cigarette warnings lower vaping interest and raise quit intentions

2025-06-02
Chapel Hill, NC — Electronic-cigarette warnings are effective in discouraging vaping, with warnings specific to health harms being generally more effective than warnings about e-cigarette addiction, according to a meta-analysis of 24 studies conducted by University of North Carolina Lineberger Comprehensive Cancer Center researchers and their colleagues. The researchers also found no negative unintended consequences of e-cigarette warnings, such as encouraging people to smoke cigarettes instead of vaping. The results will be published in JAMA Internal Medicine on June 2. “This is the first meta-analysis that has tested the effectiveness of e-cigarette warnings ...

Record high: Study finds growing cannabis use among older adults

2025-06-02
Marijuana use among older adults in the US has reached a new high, with 7 percent of adults aged 65 and over who report using it in the past month, according to an analysis led by researchers with the Center for Drug Use and HIV/HCV Research (CDUHR) at the NYU School of Global Public Health.  Their findings, published in JAMA Internal Medicine, also show that the profile of those who use cannabis has changed in recent years, with pronounced increases in use by older adults who are college-educated, married, female, and have higher incomes. “Our study shows that ...

Trends in past-month cannabis use among older adults

2025-06-02
About The Study: Between 2021 and 2023, prevalence of current cannabis use increased among adults age 65 or older nationally, with key demographic subgroups experiencing marked increases. Adults with the highest incomes initially had the lowest prevalence of cannabis use vs other income levels, but by 2023, they had the highest prevalence, which may indicate better access to medical cannabis given its costs.  Corresponding Author: To contact the corresponding author, Benjamin H. Han, MD, email b2han@health.ucsd.edu. To ...

How to create aqueous 100 nm-sized materials with polycavities

2025-06-02
While molecues with a single cavity have been extensively studied in solution, the solution state functions of polycavity materials remain elusive owing to their synthetic inaccessibility. Porous aromatic polymers (PAPs) are synthesized in a single step and offer polymeric cavity frameworks with high stability, which are applicable to gas and molecule adsorption/separation only in the solid state. Due to their strong aggregation-derived insoubility, unsubstituted PAPs cannot be used in any solvent until now. To move the functions of PAPs from the solid to the solution ...

Epilepsy is more common in patients with frontotemporal dementia than expected

2025-06-02
According to a recent study, in patients with frontotemporal dementia (FTD), epileptic seizures are significantly more common than previously known. The discovery deepens understanding of the symptoms of this memory disorder and emphasises the importance of taking epileptic seizures into account in the treatment and monitoring of patients.   Coordinated by Neurocenter Finland, this major project by the University of Eastern Finland and the University of Oulu examined the prevalence of epilepsy in patients with FTD. The research dataset ...

Pre-operative THP leads to a pCR in two-thirds of early-stage HER2+ ER- breast cancer patients

2025-06-02
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less intensive, reduced chemotherapy treatment approach is currently being evaluated in the CompassHER2 pCR trial (EA1181, NCT04266249) by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). While longer follow-up is needed to assess long-term outcomes, pathologic complete response (pCR) rates and predictors of ...

Immune system discovery reveals potential solution to Alzheimer’s

2025-06-02
A new way of thinking about Alzheimer’s disease has yielded a discovery that could be the key to stopping the cognitive decline seen in Alzheimer’s and other neurodegenerative diseases. University of Virginia School of Medicine scientists have been investigating the possibility that Alzheimer’s is caused, at least in part, by the immune system’s wayward attempts to fix DNA damage in the brain. Their research reveals that an immune molecule called STING drives the formation of the harmful plaques and protein ...

LAST 30 PRESS RELEASES:

Can early exposure to dogs lessen genetic susceptibility to eczema?

Are stress and resilience factors among gender and sexual minority adolescents related to sleep health?

How does a common plant pathogen affect urban trees, and how should it be managed?

Which seeds are best to include in annual flowering seed mixes to attract insect pollinators?

How useful are states’ adolescent social media laws?

Evidence to support state policies regulating teen use of social media is limited, study finds

Pet dogs could combat genetic eczema risk in children

A threesome that hatches potato parasites

Young people discover the technologies shaping their future in the World Economic Forum and Frontiers for Young Minds collection

Real-time 3D visualization reveals potent antibacterial and antibiofilm activity against superbacteria

Abnormal uterine bleeding and insulin resistance are on the rise: Is there a connection?

Eye wear breakthrough: MXene-coated lenses for safer and smarter wearables

‘AI scientist’ suggests combinations of widely available non-cancer drugs can kill cancer cells

Phage therapy at a turning point: Global experts converge in Berlin to shape the future of antimicrobial medicine

Low calorie diets linked to heightened risk of depressive symptoms

Bronchiolitis, monoclonal antibody halves hospitalizations of children younger than six months old

Mum’s obesity linked to child’s heightened hospital admission risk for infection

Millions of new solar system objects to be found and ‘filmed in technicolor’ – studies predict

Pitt study has upended decades-old assumptions about brain plasticity

Hertz Foundation partners with Analog Devices to empower future leaders in analog, digital and software technology solutions

Would you hand over your health data if it meant better care?

Study examines how well wearable tech tracks fitness metrics

Dr. Nikolaos Koundouros wins 2025 Tri-Institutional Breakout Award

Low vs. High blood pressure avoidance in non-cardiac surgery: Neurocognitive outcomes unchanged

Telehealth can improve care for cats with chronic health issues

Researchers develop innovative model to study sense of smell

Birds may be drinking on the wing, but in moderation

Collaboration can unlock Australia’s energy transition without sacrificing natural capital

Study identifies proteins involved in the effectiveness of immunotherapy against blood cancer

Cannabis extract could treat fungal diseases

[Press-News.org] Researchers find early driver of prostate cancer aggressiveness
Study links higher expression of the gene PROX1 to aggressive change in prostate tumor cells; FDA-approved class of drugs can disable PROX1